Modulation of Serotonin Transporter Function during Fetal Development Causes Dilated Heart Cardiomyopathy and Lifelong Behavioral Abnormalities
2008

Effects of SSRIs on Fetal Development and Behavior

publication 10 minutes Evidence: moderate

Author Information

Author(s): Noorlander Cornelle W., Ververs Frederique F. T., Nikkels Peter G. J., van Echteld Cees J. A., Visser Gerard H. A., Smidt Marten P.

Primary Institution: University Medical Center Utrecht

Hypothesis

Does prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) affect fetal development and long-term behavior?

Conclusion

Prenatal fluoxetine exposure negatively impacts fetal development, leading to cardiomyopathy and increased vulnerability to anxiety disorders in adulthood.

Supporting Evidence

  • Fluoxetine showed a high placental transfer in both mice and humans.
  • 62% of fluoxetine-treated offspring died within 6 days after birth.
  • Fluoxetine exposure resulted in long-term alterations in serotonin transporter levels.
  • Fluoxetine-treated mice showed increased latency to feed, indicating anxiety-related behavior.

Takeaway

Giving certain medicines to pregnant mice can hurt their babies' hearts and make them sad or anxious when they grow up.

Methodology

Pregnant mice were treated with fluoxetine or fluvoxamine, and the effects on offspring were measured in terms of survival, heart health, and behavior.

Potential Biases

Potential bias in interpreting the effects of SSRIs due to species differences.

Limitations

The study was conducted in mice, which may not fully represent human outcomes.

Participant Demographics

Pregnant C57Bl/6-JIco mice were used in the study.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0002782

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication